These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 2195055

  • 21. Type III group B Streptococcus: functional interaction with IgG subclass antibodies.
    Givner LB, Baker CJ, Edwards MS.
    J Infect Dis; 1987 Mar; 155(3):532-9. PubMed ID: 3543156
    [Abstract] [Full Text] [Related]

  • 22. Variations in the opsonic requirements of group B streptococcus type III.
    Hastings MJ, Easmon CS.
    Br J Exp Pathol; 1981 Oct; 62(5):519-25. PubMed ID: 7028075
    [Abstract] [Full Text] [Related]

  • 23. Requirements for the opsonic activity of human IgG directed to type 6 group A streptococci: net basic charge and intact Fc region.
    Fischetti VA.
    J Immunol; 1983 Feb; 130(2):896-902. PubMed ID: 6336773
    [Abstract] [Full Text] [Related]

  • 24. Opsonic and protective activity of immunoglobulin, modified immunoglobulin, and serum against neonatal Escherichia coli K1 infection.
    Bortolussi R, Fischer GW.
    Pediatr Res; 1986 Feb; 20(2):175-8. PubMed ID: 3511443
    [Abstract] [Full Text] [Related]

  • 25. Comparison of group B streptococcal hyperimmune globulin and standard intravenously administered immune globulin in neonates.
    Weisman LE, Anthony BF, Hemming VG, Fischer GW.
    J Pediatr; 1993 Jun; 122(6):929-37. PubMed ID: 8501574
    [Abstract] [Full Text] [Related]

  • 26. Opsonic activity of immunoglobulin prepared for intravenous use.
    Hetherington SV, Giebink GS.
    J Lab Clin Med; 1984 Dec; 104(6):977-86. PubMed ID: 6502004
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Impaired phagocytosis and opsonisation towards group B streptococci in preterm neonates.
    Källman J, Schollin J, Schalèn C, Erlandsson A, Kihlström E.
    Arch Dis Child Fetal Neonatal Ed; 1998 Jan; 78(1):F46-50. PubMed ID: 9536841
    [Abstract] [Full Text] [Related]

  • 29. Comparative protective activity of human monoclonal and hyperimmune polyclonal antibody against group B streptococci.
    Hill HR, Gonzales LA, Knappe WA, Fischer GW, Kelsey DK, Raff HV.
    J Infect Dis; 1991 Apr; 163(4):792-8. PubMed ID: 2010632
    [Abstract] [Full Text] [Related]

  • 30. Demonstration of opsonic activity and in vivo protection against group B streptococci type III by Streptococcus pneumoniae type 14 antisera.
    Fischer GW, Lowell GH, Crumrine MH, Bass JW.
    J Exp Med; 1978 Sep 01; 148(3):776-86. PubMed ID: 29937
    [Abstract] [Full Text] [Related]

  • 31. An IgA monoclonal antibody directed against type III antigen on group B streptococci acts as an opsonin.
    Bohnsack JF, Hawley MM, Pritchard DG, Egan ML, Shigeoka AO, Yang KD, Hill HR.
    J Immunol; 1989 Nov 15; 143(10):3338-42. PubMed ID: 2681414
    [Abstract] [Full Text] [Related]

  • 32. Intravenous immunoglobulin in neonatal group B streptococcal disease. Pharmacokinetic and safety studies in monkeys and humans.
    Fischer GW, Weisman LB, Hemming VG, London WT, Hunter KW, Bosworth JM, Sever JL, Wilson SR, Curfman BL.
    Am J Med; 1984 Mar 30; 76(3A):117-23. PubMed ID: 6424443
    [Abstract] [Full Text] [Related]

  • 33. Opsonic effect of jacalin and human immunoglobulin A on type II group B streptococci.
    Payne NR, Concepcion NF, Anthony BF.
    Infect Immun; 1990 Nov 30; 58(11):3663-70. PubMed ID: 2228238
    [Abstract] [Full Text] [Related]

  • 34. Properties of human anti-group B streptococcal type III capsular IgG antibody.
    Feldman RG, Breukels MA, David S, Rijkers GT.
    Clin Immunol Immunopathol; 1998 Feb 30; 86(2):161-9. PubMed ID: 9473378
    [Abstract] [Full Text] [Related]

  • 35. Functional activity of class-specific antibodies to type III, group B streptococcus.
    Campbell JR, Baker CJ, Metzger TG, Edwards MS.
    Pediatr Res; 1988 Jan 30; 23(1):31-4. PubMed ID: 3277150
    [Abstract] [Full Text] [Related]

  • 36. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.
    Kasper DL, Paoletti LC, Wessels MR, Guttormsen HK, Carey VJ, Jennings HJ, Baker CJ.
    J Clin Invest; 1996 Nov 15; 98(10):2308-14. PubMed ID: 8941648
    [Abstract] [Full Text] [Related]

  • 37. Development of a multiplexed opsonophagocytic killing assay (MOPA) for group B Streptococcus.
    Choi MJ, Noh JY, Cheong HJ, Kim WJ, Lin SM, Zhi Y, Lim JH, Lim S, Seo HS, Song JY.
    Hum Vaccin Immunother; 2018 Jan 02; 14(1):67-73. PubMed ID: 28933634
    [Abstract] [Full Text] [Related]

  • 38. Opsonic activity of commercially available standard intravenous immunoglobulin preparations.
    Weisman LE, Cruess DF, Fischer GW.
    Pediatr Infect Dis J; 1994 Dec 02; 13(12):1122-5. PubMed ID: 7892082
    [Abstract] [Full Text] [Related]

  • 39. Functional bacterial opsonic activity of human amniotic fluid.
    Cone MJ, Steele RW, Marmer DJ, Hill DE.
    Am J Obstet Gynecol; 1982 Feb 01; 142(3):282-7. PubMed ID: 7039315
    [Abstract] [Full Text] [Related]

  • 40. Assessment of group B streptococcal opsonins in human and rabbit serum by neutrophil chemiluminescence.
    Hemming VG, Hall RT, Rhodes PG, Shigeoka AO, Hill HR.
    J Clin Invest; 1976 Dec 01; 58(6):1379-87. PubMed ID: 62761
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.